14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
NMR vs SMFG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Sumitomo Mitsui Financial Group, Inc (SMFG) captures the overall head-to-head institutional edge over Nomura Holdings, Inc (NMR) on higher Unified Composite conviction (59.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMR wins 3–2 across the 6-pillar growth and valuation breakdown. NMR trades at $9.34 (12.7x Forward P/E, 25.1% operating margin) versus SMFG at $23.34 (13.8x Forward P/E, 32.1% operating margin).
Growth vs. Quality Trade-Off: SMFG earns the overall head-to-head edge with a stronger Unified Composite Score (59.1/100 HOLD vs. NMR 44.5/100 HOLD) and 1.17β · 34% Vol risk profile, whereas NMR leads top-line expansion (+17.9% YoY revenue growth, 0.81x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile SMFG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NMR vs SMFG. Trailing 12-month operating profitability (NMR 25.1% vs SMFG 32.1%) and valuation multiples (NMR 12.7x vs SMFG 13.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Capital Markets value chain with $28.3B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment52.3% of Rev ($7.77B)
90D Engineering Disclosures0 Published
SMFG Moat ProfileHigh-Margin Pricing Power Moat
Banks - Diversified Operator
Competes within the Banks - Diversified value chain with $156.3B market capitalization and 32.1% operating margin.
OpEx & R&D Reinvestment67.9% of Rev ($27.2B)
90D Engineering Disclosures0 Published
Investor FAQ NMR vs SMFG Key Questions & Quantitative Answers
As of Nov 17, 2026, Sumitomo Mitsui Financial Group, Inc (SMFG) captures the overall head-to-head institutional edge over Nomura Holdings, Inc (NMR) on higher Unified Composite conviction (59.1/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, R&D & Supply-Chain Moat), while NMR wins 3–2 across the 6-pillar growth and valuation breakdown. NMR trades at $9.34 (12.7x Forward P/E, 25.1% operating margin) versus SMFG at $23.34 (13.8x Forward P/E, 32.1% operating margin). Growth vs. Quality Trade-Off: SMFG earns the overall head-to-head edge with a stronger Unified Composite Score (59.1/100 HOLD vs. NMR 44.5/100 HOLD) and 1.17β · 34% Vol risk profile, whereas NMR leads top-line expansion (+17.9% YoY revenue growth, 0.81x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile SMFG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NMR leads the Growth & Scale pillar: NMR posts +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin), compared with SMFG at +7.5% YoY revenue growth and -8.5% YoY earnings growth on $40.1B TTM revenue (100.0% gross margin, 32.1% operating margin). On trailing 12-month operating scale, NMR generates $14.9B in USD-normalized revenue versus $40.1B for SMFG. In operating R&D and SG&A reinvestment, NMR deploys 52.3% of Rev ($7.77B) (0 90-day corporate R&D disclosures) versus 67.9% of Rev ($27.2B) (0 disclosures) for SMFG.
NMR screens cheaper on headline valuation multiples. NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin), whereas SMFG trades at 13.8x Forward P/E, 15.0x Trailing P/E, 2.02x PEG, and 3.9x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NMR (11.5% ROE) versus SMFG (8.1% ROE) capital efficiency.
In options market volatility and institutional positioning, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk). By comparison, SMFG carries 27.8% implied volatility (23rd %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.17β · 34% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.